Skip to Content

Zemplar (paricalcitol) Disease Interactions

There are 4 disease interactions with Zemplar (paricalcitol):

Major

Paricalcitol (Includes Zemplar) ↔ Arrhythmia

Severe Potential Hazard, Moderate plausibility

Applies to: Arrhythmias

Paricalcitol, a vitamin D analog, reduces hyperparathyroidism associated with chronic renal failure without significant increase in serum calcium levels. Serum calcium and phosphate concentrations can increase during therapy with paricalcitol and may exacerbate arrhythmias, particularly in patients receiving cardiac glycosides. Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias. Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended. .

References

  1. "Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical, Abbott Park, IL.
Major

Vitamin D Analogs (Includes Zemplar) ↔ Electrolyte Imbalance

Severe Potential Hazard, High plausibility

Applies to: Phosphate Imbalance

Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or renal systems or other soft tissue calcifications. A solubility product (Serum Calcium X Phosphate) should not exceed 70. Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.

References

  1. "Product Information. Calciferol (ergocalciferol)." Schwarz Pharma, Mequon, WI.
  2. "Product Information. Calderol (calcifediol)." Organon, West Orange, NJ.
  3. "Product Information. Rocaltrol (calcitriol)." Roche Laboratories, Nutley, NJ.
  4. "Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical, Abbott Park, IL.
View all 4 references
Major

Vitamin D Analogs (Includes Zemplar) ↔ Hypercalcemia

Severe Potential Hazard, Moderate plausibility

Applies to: Hypercalcemia, Malabsorption Syndrome

Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.

Moderate

Paricalcitol (Includes Zemplar) ↔ Hepatobiliary Dysfunction

Moderate Potential Hazard, Moderate plausibility

Applies to: Biliary Obstruction, Liver Disease

Paricalcitol is metabolized by the liver. Parent compound and metabolites are primarily eliminated by in the bile and feces. Paricalcitol metabolites have not been characterized or identified. Metabolic and therapeutic activity of paricalcitol may be altered in patients with hepatic impairment. Therapy with paricalcitol should be administered cautiously in patients with hepatobiliary dysfunction. Clinical monitoring of hepatobiliary function, parathyroid hormone and calcium levels is recommended.

References

  1. "Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical, Abbott Park, IL.

Zemplar (paricalcitol) drug Interactions

There are 208 drug interactions with Zemplar (paricalcitol)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide